Nang Kuang Pharmaceutical Co., Ltd. (TPE:1752)
28.00
-1.35 (-4.60%)
Nov 20, 2026, 1:30 PM CST
Nang Kuang Pharmaceutical Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,828 | 3,767 | 4,156 | 5,383 | 6,453 | 3,888 | |
Market Cap Growth | -26.61% | -9.36% | -22.80% | -16.59% | 65.97% | -2.78% |
Enterprise Value | 3,416 | 4,208 | 4,435 | 5,681 | 6,651 | 4,113 |
Last Close Price | 28.00 | 35.50 | 37.45 | 46.71 | 53.99 | 30.95 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 15.13 | 15.41 | 17.07 | 27.13 | 18.33 | 19.83 |
Forward PE | - | 14.92 | 17.95 | 19.68 | 21.30 | 14.55 |
PS Ratio | 1.35 | 1.74 | 1.89 | 2.50 | 3.33 | 2.18 |
PB Ratio | 1.16 | 1.51 | 1.72 | 2.26 | 2.68 | 1.74 |
P/TBV Ratio | 1.17 | 1.52 | 1.72 | 2.27 | 2.68 | 1.74 |
P/FCF Ratio | 483.36 | 20.22 | - | 119.36 | 23.44 | 9.71 |
P/OCF Ratio | 11.03 | 8.12 | 8.91 | 15.71 | 17.48 | 6.99 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.64 | 1.95 | 2.02 | 2.64 | 3.43 | 2.31 |
EV/EBITDA Ratio | 7.86 | 8.80 | 9.01 | 12.89 | 13.39 | 9.49 |
EV/EBIT Ratio | 13.48 | 14.23 | 14.30 | 21.86 | 20.68 | 16.16 |
EV/FCF Ratio | 583.94 | 22.59 | - | 125.98 | 24.16 | 10.27 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.31 | 0.26 | 0.26 | 0.30 | 0.17 | 0.24 |
Debt / EBITDA Ratio | 1.75 | 1.37 | 1.29 | 1.60 | 0.82 | 1.23 |
Debt / FCF Ratio | 130.38 | 3.52 | - | 15.65 | 1.49 | 1.33 |
Net Debt / Equity Ratio | 0.24 | 0.13 | 0.14 | 0.14 | 0.00 | 0.05 |
Net Debt / EBITDA Ratio | 1.35 | 0.65 | 0.68 | 0.74 | 0.01 | 0.26 |
Net Debt / FCF Ratio | 99.92 | 1.67 | -5.79 | 7.25 | 0.02 | 0.29 |
Asset Turnover | 0.55 | 0.57 | 0.57 | 0.58 | 0.55 | 0.53 |
Inventory Turnover | 1.81 | 1.93 | 1.97 | 1.75 | 1.63 | 1.61 |
Quick Ratio | 0.58 | 0.67 | 0.63 | 0.59 | 0.76 | 0.72 |
Current Ratio | 1.42 | 1.40 | 1.27 | 1.20 | 1.58 | 1.39 |
Return on Equity (ROE) | 7.64% | 9.93% | 10.14% | 8.29% | 15.14% | 8.82% |
Return on Assets (ROA) | 4.92% | 6.40% | 6.35% | 5.33% | 10.04% | 5.86% |
Return on Invested Capital (ROIC) | 7.33% | 8.91% | 9.12% | 9.42% | 11.56% | 8.91% |
Return on Capital Employed (ROCE) | 9.00% | 10.70% | 11.60% | 10.10% | 12.60% | 10.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Nov '26 Nov 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 6.61% | 6.49% | 5.86% | 3.69% | 5.46% | 5.04% |
FCF Yield | 0.21% | 4.95% | -1.40% | 0.84% | 4.27% | 10.30% |
Dividend Yield | 5.71% | - | 3.89% | 3.75% | 3.60% | 4.67% |
Payout Ratio | 85.81% | 66.11% | 82.98% | 117.07% | 51.64% | 82.39% |
Buyback Yield / Dilution | -0.26% | -0.02% | -0.10% | 0.08% | 0.01% | -0.03% |
Total Shareholder Return | 5.45% | -0.02% | 3.79% | 3.83% | 3.61% | 4.64% |